Pharmaceutical ProductCached Profile
PENUMBRA SYSTEM
Active Ingredients (Generic):Unmapped
Therapeutic Area: Neurointervention
LIFETIME PROMOTIONAL SPEND
$505,168
General Payments Aggregated (2021–2025)
Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.
FDA Patient Safety Profile
Dynamic safety indicators compiled from official FDA product labels.
Active Clinical Trials
Clinical studies listing this drug as an active intervention.
LOTUS: Global Acute Stroke Study Utilizing Penumbra System
TERMINATEDPhase N/ANCT04157270
Immersive Virtual Reality to Decrease Postoperative Pain in Older Adults Following Elective Major Surgery: A Feasibility and Acceptability Study
COMPLETEDPhase NANCT06095661
Indian Registry (The INDigo System in Acute Lower Limb malperfusioN)
UNKNOWNPhase NANCT03386370
Top Funded Physicians (Cumulative)
Doctors receiving the highest aggregate promotional support for this product.
Dr. DONALD FREIMedical Doctor$24,653
Dr. ORLANDO DIAZMedical Doctor$23,421
Dr. ROBERT STARKEMedical Doctor$23,356
Dr. ALEJANDRO SPIOTTAMedical Doctor$19,651
Dr. GUILHERME DABUSMedical Doctor$19,493
Drug Marketing Payments Log
Federal registry records of promotional speaking, consulting, meals, and offsets.
Year:
2025
2025
2024
2023
2022
2021
Querying Open Payments Database
Fetching live CMS.gov records for PENUMBRA SYSTEM...